Panbela Therapeutics EV/EBITDA
¿Qué es el EV/EBITDA de Panbela Therapeutics?
El EV/EBITDA de Panbela Therapeutics Inc. es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Panbela Therapeutics
¿Qué hace Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Empresas con ev/ebitda similar a Panbela Therapeutics
- Guild Esports Plc tiene EV/EBITDA de N/A
- Delta Drone SA tiene EV/EBITDA de N/A
- Canaccord Genuity tiene EV/EBITDA de N/A
- Lordstown Motors tiene EV/EBITDA de N/A
- Tesla Exploration tiene EV/EBITDA de N/A
- DigiCrypts Blockchain Solutions tiene EV/EBITDA de N/A
- Panbela Therapeutics tiene EV/EBITDA de N/A
- Hapbee Technologies tiene EV/EBITDA de N/A
- China Parenting Network tiene EV/EBITDA de N/A
- X4 Pharmaceuticals tiene EV/EBITDA de N/A
- Delta Drone SA tiene EV/EBITDA de N/A
- Diablo Resources Ltd tiene EV/EBITDA de N/A
- cbdMD Inc tiene EV/EBITDA de N/A